Comparative Study of Different I-131 Doses in Graves' Disease
NCT ID: NCT02114619
Last Updated: 2014-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
450 participants
INTERVENTIONAL
2013-05-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients
NCT01560299
Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism
NCT01039818
Factors Affecting Timing of Hypothyroidism Following Radioactive Iodine Therapy Patients With Graves Disease
NCT05643365
Iodine Supplementation in Graves' Hyperthyroidism
NCT06540469
Radioactive Iodide Therapy for Pediatric Graves' Disease
NCT01269749
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose of I-131
Patients with Graves' disease who will be treated with I-131, using 100 microcurie per gram (uCi/gr) of thyroid weight
Low dose of I-131
We wil administer 100 micro currie of iodine per thyroid gram
Intermediate dose
Patients with Graves' disease who will be treated with 150 microcurie (uCi) of I-131 per gram of thyroid weight.
Intermediate dose
We will administer 150 micro currie of iodine per thyroid gram
High dose
Patients with Graves' disease who will be treated with I-131 using 200 uCi/gr of thyroid weight.
High dose
We will administer 200 micro currie of iodine per thyroid gram
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low dose of I-131
We wil administer 100 micro currie of iodine per thyroid gram
Intermediate dose
We will administer 150 micro currie of iodine per thyroid gram
High dose
We will administer 200 micro currie of iodine per thyroid gram
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mashhad University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
S.R.ZAKAVI
Head of Nuclear Medicine Research Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Narjess Ayati, MD, FEBNM
Role: STUDY_DIRECTOR
Nuclear Medicine Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nuclear Medicine Research Center, Ghaem Hospital
Mashhad, Khorasan-Razavi, Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
920800
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.